{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:42:47Z","timestamp":1793565767303,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.yrtph.2024.105704","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T23:44:39Z","timestamp":1727221479000},"page":"105704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["N-Nitrosamine drug substance related impurities (NDSRIs) \u2013 A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200\u00a0Da"],"prefix":"10.1016","volume":"154","author":[{"given":"Joel","family":"Bercu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Dobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-375X","authenticated-orcid":false,"given":"James","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Trejo-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.yrtph.2024.105704_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103366","article-title":"Trends in small molecule drug properties: a developability molecule assessment perspective","volume":"27","author":"Agarwal","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yrtph.2024.105704_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105415","article-title":"Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)","volume":"142","author":"Bercu","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105704_bib3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A nitrite excipient database: a useful tool to support N-nitrosamine risk assessments for drug products","volume":"112","author":"Boetzel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105704_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4939-2285-7_11","article-title":"Computational approaches to developing short cyclic peptide modulators of protein-protein interactions","volume":"1268","author":"Duffy","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.yrtph.2024.105704_bib7","article-title":"Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products","volume":"18","year":"2023","journal-title":"02 October 2023, EMA\/409815\/2020 Rev"},{"key":"10.1016\/j.yrtph.2024.105704_bib8","first-page":"6","article-title":"Appendix 1: acceptable intakes established for N-nitrosamines reference number: EMA\/72902\/2024","volume":"4","year":"2024","journal-title":"Rev"},{"key":"10.1016\/j.yrtph.2024.105704_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105459","article-title":"Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: learnings from N-nitrosamine case studies","volume":"143","author":"Felter","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105704_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105505","article-title":"Nitrosamine acceptable intakes should consider variation in molecular weight: the implication of stoichiometric DNA damage","volume":"145","author":"Fine","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105704_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-3835(94)90182-1","article-title":"Effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on N-nitrosobis(2-oxopropyl)amine (BOP)-initiated carcinogenesis in hamsters","volume":"86","author":"Furukawa","year":"1994","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105704_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-1110(87)90026-1","article-title":"N-nitrosamines: bacterial mutagenesis and in vitro metabolism","volume":"186","author":"Guttenplan","year":"1987","journal-title":"Mutat. Res."},{"issue":"8","key":"10.1016\/j.yrtph.2024.105704_bib15","first-page":"645","article-title":"Complete inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced rat lung tumorigenesis and favorable modification of biomarkers by phenethyl isothiocyanate","volume":"5","author":"Hecht","year":"1996","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.yrtph.2024.105704_bib16","article-title":"Smokeless tobacco and some tobacco-specific N-nitrosamines","volume":"89","year":"2007","journal-title":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (Lyon, France)"},{"key":"10.1016\/j.yrtph.2024.105704_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105672","article-title":"Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine","volume":"152","author":"Jolly","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105704_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1021\/acs.chemrestox.2c00380","article-title":"Quantum-mechanical approach to predicting the carcinogenic potency of N-nitroso impurities in pharmaceuticals","volume":"36","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105704_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA)","volume":"150","author":"Kruhlak","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105704_bib23","series-title":"See Lhasa Carcinogenicity Database 2.3 Release Notes","article-title":"Lhasa carcinogenicity database","year":"2024"},{"key":"10.1016\/j.yrtph.2024.105704_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0147-6513(82)90033-1","article-title":"Dose-response studies with nitroso-1,2,3,6-tetrahydropyridine and dinitrosohomopiperazine in F344 rats","volume":"6","author":"Lijinsky","year":"1982","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"9","key":"10.1016\/j.yrtph.2024.105704_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105704_bib26","author":"Oliveira"},{"issue":"23","key":"10.1016\/j.yrtph.2024.105704_bib27","first-page":"6912","article-title":"Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines","volume":"48","author":"Rivenson","year":"1988","journal-title":"Cancer Res., 1"},{"issue":"5","key":"10.1016\/j.yrtph.2024.105704_bib28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2024.105704_bib29","article-title":"Mutagenic impurities in pharmaceuticals: a critical assessment of the cohort of concern with a focus on N-nitrosamines","volume":"141","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105704_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105247","article-title":"Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines","volume":"135","author":"Trejo-Martin","year":"2022","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105704_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104749","article-title":"Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data","volume":"116","author":"Thresher","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105704_bib32","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm021053p","article-title":"A comparison of physiochemical property profiles of development and marketed oral drugs","volume":"46","author":"Wenlock","year":"2015","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.yrtph.2024.105704_bib33","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1021\/acs.chemrestox.2c00217","article-title":"Predicting DNA-reactivity of N-nitrosamines: a quantum chemical approach","volume":"35","author":"Wenzel","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105704_bib34","series-title":"Risk (Re) Assessment of N-Methyl-N-Nitrosophenethylamine for Use in Computing Acceptable Intake Levels of N-Nitrosamine Drug Substance-Related Impurities SOT 62nd Annual Meeting & ToxExpo","author":"Woolley","year":"2022"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T03:17:48Z","timestamp":1733282268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"alternative-id":["S0273230024001454"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105704","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Nitrosamine drug substance related impurities (NDSRIs) \u2013 A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200\u00a0Da","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105704"}}